The private sector will bear the brunt of costs from
combined Senate legislation on track-and-trace and compounding,
according to a new federal cost estimate that casts doubt on an already
precarious legislative effort. A Monday report from the Congressional
Budget Office (CBO) estimates that S. 959, the Pharmaceutical Quality, Security and Accountability Act, will have little impact on the federal government.
Drug Industry Daily
Drug Industry Daily
No comments:
Post a Comment